Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838391 · ClinicalTrials.gov registry record · NA
Adaptive Radiation in Anal Cancer
A NA study of Anal Squamous Cell Carcinoma, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05838391: Recruiting NA study of Anal Squamous Cell Carcinoma, sponsored by Columbia University.
NCT05838391 is a NA study of Anal Squamous Cell Carcinoma that is actively recruiting participants, run by Columbia University. The registered enrollment target is 20 participants, below the 89-participant average among 5 other Anal Squamous Cell Carcinoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05838391, a NA study of Anal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan based on the anatomy of the day) may help to maximize the dose to the tumor and minimize the radiation dose to the normal surrounding organs.
Primary Outcome
This is defined by the time the first cone beam computed tomography to the end of treatment delivery for each treatment.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG 5-Fluorouracil
- RADIATION Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery
- DRUG Mitomycin-C
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-05-18 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT05838391 shows while recruiting
NCT05838391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 89-participant average among 5 other Anal Squamous Cell Carcinoma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Anal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT05838391 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05838391 about?
NCT05838391 is a clinical study titled "Adaptive Radiation in Anal Cancer". This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan base...
What is the current status of trial NCT05838391?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2023-05-18. Estimated completion is 2028-12-31.
What conditions does trial NCT05838391 study?
This clinical trial studies the following conditions: Anal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05838391?
The interventions under investigation include: Capecitabine (DRUG), 5-Fluorouracil (DRUG), Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery (RADIATION), Mitomycin-C (DRUG).
Who is sponsoring clinical trial NCT05838391?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05838391 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
RECRUITING · Phase 2
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 1 Study in Participants With Advanced Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI